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INTRODUCTION
Ras proteins are signal switch molecules that regulate cell fate by cycling between active, guanosine triphosphate (GTP)-bound (Ras-GTP) and inactive, guanosine diphosphate (GDP)-bound (Ras-GDP) conformations (1, 2) . Cancer-associated mutant RAS alleles encode oncogenic proteins that accumulate in the GTP-bound conformation because of a defective intrinsic guanosine triphosphatase (GTPase) activity and their resistance to GTPaseactivating proteins (GAPs) (1) (2) (3) . On the basis of the high prevalence of somatic RAS mutations in many lethal human malignancies, reversing the biochemical consequences of oncogenic Ras signaling is of fundamental importance for reducing the worldwide burden of cancer. However, the Ras GTPase switch poses extraordinary problems for anticancer drug development because an "ideal" agent must restore normal GTPase activity and responsiveness to GAPs (that is, it must repair a "broken" enzyme) in the context of a highly constrained domain of Ras in which the g phosphate of GTP interacts with the "arginine finger" of GAPs (1) (2) (3) . On the basis of the assumption that oncogenic Ras-GTP makes cancer cells less reliant on growth factors for survival and proliferation by constitutively activating downstream signaling pathways, intensive efforts are focusing on developing and evaluating small-molecule inhibitors of Ras effectors, particularly components of the phosphoinositide 3-kinase (PI3K)-Akt-mammalian target of rapamycin (mTOR) and Raf-mitogen-activated or extracellular signal-regulated protein kinase kinase (MEK)-extracellular signal-regulated kinase (ERK) pathways (4) . Recent studies also raise the possibilities of therapeutically targeting other domains of Ras oncoproteins (5) or interfering with their posttranslational processing (6, 7) .
Juvenile myelomonocytic leukemia (JMML) and chronic myelomonocytic leukemia (CMML) are myeloproliferative neoplasms (MPNs) that frequently contain "driver" mutations in genes encoding components of Ras signaling networks such as NRAS, KRAS, PTPN11, CBL, and NF1 (8, 9) . Germline PTPN11, CBL, and NF1 mutations confer an increased risk of JMML, which implicates hyperactive Ras as initiating this aggressive leukemia. Bone marrow cells from JMML patients form granulocyte-macrophage colony-forming unit (CFU-GM) colonies in the absence of cytokine growth factors and at very low concentrations of granulocyte-macrophage colonystimulating factor (GM-CSF). This cellular hallmark of JMML is also observed in bone marrow cells from Mx1-Cre, Kras G12D mice (10, 11) . These mice express oncogenic Kras G12D from its endogenous locus in hematopoietic cells and develop a fatal MPN that recapitulates many features of CMML and JMML (10) (11) (12) .
Although Ras-GTP abundance is constitutively increased in bone marrow cells from Mx1-Cre, Kras G12D mice compared to that in cells from wildtype mice, the amounts of phosphorylated Akt and ERK (pAkt and pERK) in cells from these mice are not changed or only minimally increased compared to those in wild-type mice. Bone marrow cells from both wild-type and Mx1-Cre, Kras G12D mice exhibit markedly increased pAkt and pERK abundance in response to stimulation with GM-CSF (10) . Consistent with these biochemical data, CFU-GM colony growth is greatly enhanced by GM-CSF (10, 12) . Similarly, mouse embryonic fibroblasts from Mx1-Cre, Kras G12D mice show little or no basal activation of canonical effector pathways despite their enhanced abundance of Ras-GTP, and they exhibit marked increases in pERK and pAkt abundances in response to epidermal growth factor (13, 14) . Administering PD0325901, a potent and selective MEK inhibitor, to Mx1-Cre, Kras G12D mice with MPN results in substantial hematologic improvement, characterized by a restoration of normal white blood cell counts, an improvement in anemia, and a reduction in splenic enlargement (15) . This observation provides direct evidence that aberrant Raf-MEK-ERK signaling underlies the aberrant proliferation of hematopoietic cells in vivo in this model of human MPN. Understanding the biochemical mechanisms required for the full activation of oncogenic Ras in response to growth factor stimulation might therefore reveal new therapeutic targets.
On the basis of the extensive cell biologic, genetic, and preclinical data implicating aberrant GM-CSF signaling in the pathogenesis of JMML, we combined phospho-flow cytometric analysis and pharmacological pathway mapping (16) to clarify the molecular mechanisms linking the stimulation of primary hematopoietic cells with GM-CSF to the activation of ERK (11, 15, (17) (18) (19) . Here, we show that phospholipase C-g (PLC-g) and PI3K were essential for efficient Ras and ERK activation and that analogs of diacylglycerol (DAG), the second messenger generated by PLC-g, bypassed this requirement. Despite having substantially increased amounts of Ras-GTP compared to hematopoietic cells from wild-type mice, hematopoietic cells from Mx1-Cre, Kras G12D mice remained dependent on PLC-g and PI3K for efficient activation of ERK. Inhibitors of PLC-g and PI3K also interfered with ERK phosphorylation and activation in response to stem cell factor (SCF) in immature populations of bone marrow cells from wild-type and Mx1-Cre, Kras G12D mice that were enriched for hematopoietic stem cells (HSCs) and leukemia-initiating cells. Studies of hematopoietic progenitor colony growth and of cytokine signaling after treatment of mice with a PI3K inhibitor confirmed the physiological relevance of this pathway. Together, these data raise the possibility that targeting proteins that function upstream of oncogenic Ras-alone or in combination with other therapies-may represent a viable strategy for treating cancers, particularly those that are highly responsive to growth factors. In addition, these data suggest that PI3K inhibitors could contribute to myelosuppression by interfering with cytokine signaling networks in normal hematopoietic stem and progenitor cells.
RESULTS
PLC-g and PI3K stimulate ERK activation in hematopoietic cells from wild-type and Mx1-Cre, Kras G12D mice Compared to those of wild-type mice, the bone marrows of Mx1-Cre, Kras G12D mice contain a preponderance of myeloid cells with a corresponding loss of erythroid and lymphoid cell populations (10, 11) . These changes in cellular composition might increase the apparent response to a stimulus that acts on myeloid cells alone. Phospho-flow cytometry avoids this problem by analyzing signaling at the single-cell level in a heterogeneous tissue such as bone marrow (20, 21) . We therefore used this methodology to characterize cytokine responses in bone marrow cells from wild-type and Mx1-Cre, Kras G12D mice. Our analysis focused on differentiated myeloid lineage cells (mostly mature granulocytes and monocytes) that expressed the Mac1 and Gr1 cell surface markers (M + G + cells), as well as the c-Kit (Fig. 1A and fig. S2A ). Although the bone marrow of Mx1-Cre, Kras G12D mice contained more GM-CSF-responsive M + G + cells than did the bone marrow from wild-type mice ( fig. S1 ), the extent of ERK phosphorylation within responding cells was comparable in wild-type and Kras G12D cells (Fig. 1A and fig. S2A , green curves). Kras G12D cells were dependent on GM-CSF stimulation to activate ERK (Fig. 1A and fig. S2A ).
Upon ligand binding, the common b chain of the GM-CSF receptor is phosphorylated by Janus-activated kinase 2 (JAK2), generating docking sites for signaling molecules and adaptor proteins (22) . To investigate the molecular mechanism linking GM-CSF to ERK activation, we exposed bone marrow cells from wild-type and Mx1-Cre, Kras G12D mice to a panel of kinase inhibitors. Cells incubated with the MEK inhibitor PD0325901 (23) served as a positive control for measuring inhibition of ERK phosphorylation (Fig. 1A and fig. S2A ). As expected, JakI, an inhibitor of JAK proteins, abrogated GM-CSF-dependent ERK phosphorylation in wild-type and Mx1-Cre, Kras G12D bone marrow cells. In contrast, GM-CSF-dependent ERK activation was unimpaired by the Src family tyrosine kinase inhibitor PP2, despite there being a marked reduction in the total abundance of tyrosinephosphorylated proteins (Fig. 1A and fig. S2, A and B) . GM-CSF-induced ERK phosphorylation was also unimpaired in cells that were exposed to the protein kinase C (PKC) inhibitor bisindolylmaleimide I (BIM I) (Fig. 1A) . Pretreatment of cells with chemical inhibitors of PLC-g (U73122) (24, 25) or PI3K (PI-90) (26) (Fig. 1A and fig. S2A 
G
-cells that were exposed to PI-90 showed some residual ERK activation upon GM-CSF stimulation ( fig. S2A) .
SCF stimulates the proliferation of HSCs and progenitor cells through binding to the receptor tyrosine kinase (RTK) c-Kit. Somatic KIT mutations that constitutively activate the intrinsic kinase activity of c-Kit are found in acute myeloid leukemia (27, 28) . We investigated the effects of small-molecule inhibitors on SCF-stimulated ERK activation in K
-cells, which uniformly express c-Kit. As reported previously (21) , the phosphorylation of ERK in response to SCF was impaired in Mx1-Cre, Kras G12D cells compared to that in wild-type cells (Fig. 1B) . As expected, JakI had no effect on SCF-induced ERK activation, whereas inhibitors of Src family tyrosine kinases (PP2) markedly reduced SCF-stimulated ERK phosphorylation. Similar to our findings from experiments with cells stimulated with GM-CSF, PKC inhibitors had no effect on the ability of SCF to stimulate ERK activation. We found that U73122 and PI-90 markedly reduced the ability of SCF to induce ERK phosphorylation in K + M -
-cells from wild-type and Mx1-Cre, Kras G12D mice (Fig. 1B) . Together, these data place PLC-g and PI3K upstream of ERK activation in GM-CSF and SCF signaling pathways in differentiated and immature myeloid lineage cells from both wild-type and Mx1-Cre, Kras G12D mice.
Inhibitors of PLC-g and PI3K have effects on Ras-GTP abundance in bone marrow from wild-type and Mx1-Cre, Kras G12D mice
To clarify the level at which PLC-g and PI3K regulated Ras-Raf-MEK-ERK signaling, we measured Ras-GTP abundance in bone marrow cells from wildtype and Mx1-Cre, Kras G12D mice before and after stimulation with GM-CSF. As expected, GM-CSF induced GTP loading on Ras in wild-type bone marrow cells. This response was reduced by chemical inhibitors of JAKs, PLC-g, or PI3K, all of which also abrogated or markedly reduced the extent of ERK phosphorylation (Fig. 1C and fig. S3 ). Whereas the PKC inhibitor BIM I also reduced the GM-CSF-dependent generation of Ras-GTP, ERK activation was normal. As expected, PD0325901 completely eliminated ERK phosphorylation in response to GM-CSF, but had no effect on Ras-GTP abundance (Fig. 1C and fig. S3C ). PI-90 and U73122 also markedly reduced Akt phosphorylation ( fig. S3D) .
Consistent with our phospho-flow cytometry data (Fig. 1, A and B) and a previous report (10) , ERK is only minimally phosphorylated in unstimulated bone marrow cells from Mx1-Cre, Kras G12D mice despite a constitutive increase in Ras-GTP abundance (Fig. 1C) . We detected equivalent abundances of Ras, PLC-g1, PLC-g2, Akt, MEK, and ERK in the bone marrow cells of wild-type and Mx1-Cre, Kras G12D mice, and therefore used actin as a general loading control for subsequent Western blotting experiments ( fig. S3A ). Upon exposure to GM-CSF, these cells robustly generated pERK without further increasing Ras-GTP abundance ( fig. S3C ). Whereas JakI, PI-90, and U73122 did not alter the high basal abundance of Ras-GTP in Mx1-Cre, Kras G12D mouse bone marrow cells, each inhibitor markedly impaired ERK activation in response to GM-CSF in these cells (Fig. 1A and fig. S3 , C and D). Together, these data place PLC-g and PI3K upstream of Ras in the Raf-MEK-ERK signaling pathway in primary bone marrow cells. We also showed that the constitutively increased abundance of Ras-GTP that resulted from endogenous oncogenic K-Ras G12D was insufficient for the efficient phosphorylation of ERK, which required cytokine and was sensitive to inhibition of PLC-g or PI3K.
To expand on our observations of the effects of PI3K inhibition, we treated M + G + cells with PI-103, a dual-specificity inhibitor of PI3K and mTOR that is structurally unrelated to PI-90 (26) , and with isoformselective PI3K inhibitors (figs. S4 to S6). We found that PI-103 reduced GM-CSF-stimulated ERK activation as did PI-90 and that an inhibitor selective for the p110a and p110g isoforms of PI3K was more potent than were inhibitors of the p110b and p110d isoforms in reducing ERK activation in cells that were stimulated with GM-CSF (figs. S5 and S6).
To further characterize the role of PLC-g in GM-CSF signaling in bone marrow cells from wild-type and Mx1-Cre, Kras G12D mice, we examined the effects of GM-CSF on the phosphorylation of PLC-g1 and PLC-g2 (pPLC-g1 and pPLC-g2, respectively) in M + G + cells in the absence and presence of chemical inhibitors. The basal amount of pPLC-g1 was increased in Mx1-Cre, Kras G12D cells compared to that in wild-type cells, and GM-CSF stimulated the phosphorylation of both isoforms of PLC-g in cells of either genotype ( Fig. 1D and fig. S7 ). Pretreatment with U73122 abrogated this response, and JakI also potently inhibited the phosphorylation of both PLC-g1 and PLC-g2. Cells treated with PI-90 or PI-103 showed a more modest reduction in GM-CSF-dependent pPLC-g1 or PLC-g2 generation than was observed in cells treated with JakI or U73122 ( Fig. 1D and fig. S7 ).
PLC-g mediates the activation of PI3K and mitogen-activated protein kinases
To functionally study signaling networks in primary myeloid cells, we cultured mouse bone marrow cells in macrophage medium that selectively enabled the growth of bone marrow macrophage progenitor cells (BMMPCs), a relatively homogeneous population that exhibits activated Ras signaling in response to GM-CSF (29, 30) . The abundances of Ras and of other key signaling molecules were equivalent in BMMPCs grown from wild-type and Mx1-Cre, Kras G12D mice ( fig. S3B ). Western blotting analysis showed that JakI, PI-90, and U73122 inhibited GM-CSF-dependent ERK activation in BMMPCs, whereas the PKC inhibitor BIM I had no effect ( fig. S8 ). These data were consistent with the observed effects of these inhibitors on bone marrow M + G + cells (Fig. 1A and fig. S2A ). The ability to culture BMMPCs from wild-type and Mx1-Cre, Kras G12D bone marrow provided us with a robust primary cell system in which to exploit RNA interference (RNAi) to interrogate the interaction of PLC-g and PI3K in ERK activation. We constructed retroviral vectors encoding PLC-g-specific or control short hairpin RNAs (shRNAs), a neomycin resistance gene, and a fluorescent marker [green fluorescent protein (GFP) for shPLC-g1 and mCherry for shPLC-g2]. After their transduction, bone marrow cells were grown in myeloid medium that selectively enabled the growth of BMMPCs in the presence of the antibiotic G418 to increase the number of cells expressing the shRNA constructs ( fig.  S9A ). Flow cytometric analysis confirmed that most of the BMMPCs expressed GFP or mCherry (58 to 79%; fig. S9A ). Knockdown of PLC-g2 reduced the extent of ERK and Akt activation in response to GM-CSF ( Fig. 2A) , whereas knockdown of PLC-g1 with either shRNA only had modest effects on pAkt induction ( fig. S9B ).
DAG analogs bypass chemical inhibitors to activate Ras-Raf-MEK-ERK signaling in BMMPCs
Activated PLC-g hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP 2 ) to generate DAG and inositol 1,4,5-trisphosphate (IP 3 ), the latter of which mobilizes intracellular calcium ions (Ca 2+ ). These second messengers, in turn, activate PKC and guanine nucleotide exchange factors (GEFs) of the Ras guanine nucleotide-releasing protein (RasGRP) family (31) . We compared Ras-GTP abundance, as well as the extents of ERK and Akt phosphorylation, in wild-type and Mx1-Cre, Kras
G12D
BMMPCs that were exposed to GM-CSF or to the DAG mimetic phorbol 12-myristate 13-acetate (PMA). We found that PMA increased Ras-GTP and pERK abundances in BMMPCs of both genotypes, but that it had little or no effect on pAkt abundance (Fig. 2B and fig. S10A ).
GM-CSF also stimulated an increase in Ras-GTP abundance and ERK phosphorylation in BMMPCs; however, the time courses of these responses differed (A) BMMPCs that were not transduced (Unt) or were transduced with a retroviral vector expressing mCherry (mCh) or a vector encoding mCherry and one of two independent shRNAs specific for PLC-g2 (shg2-1 or shg2-2) were lysed, and the abundances of PLC-g2, pAkt, and pERK were measured by Western blotting analysis, with actin used as a loading control. (B) Effects of PMA and GM-CSF on Ras-GTP, pERK, and pAkt abundances in BMMPCs from WT and Kras G12D mice. BMMPCs from the indicated mice were treated with PMA or GM-CSF for the indicated times and lysed. Ras-GTP abundance was assessed by a Ras-RBD pull-down assay, and the abundances of pAkt and pERK were analyzed by Western blotting analysis of the same lysates. Actin was used as a loading control. (C) BMMPCs were pretreated with PI-90 or U73122 (U73) and then were left unstimulated or were stimulated with GM-CSF or PMA for 15 min. Cells were then analyzed by Western blotting for the abundances of pAkt and pERK, with actin used as a loading control. (D) Analysis of CFU-GM growth from bone marrow cells from WT and Kras G12D mice that were cultured in a saturating concentration of GM-CSF (10 ng/ml) in the absence or presence of the inhibitors JakI, PI-90, U73122, or Akt VIII. Data in (A) to (C) are from single representative experiments, and data from other independent experiments are shown in figs. S8 to S10. Data in (D) are means ± SD from three independent experiments. from those of PMA ( Fig. 2B and fig. S10B ). In contrast to PMA, GM-CSF also stimulated an increase in pAkt abundance ( Fig. 2B and figs. S3D and S10B). The extent and duration of Akt activation differed between wild-type and Mx1-Cre, Kras G12D BMMPCs. In particular, wild-type cells showed a marked response 10 to 15 min after exposure to GM-CSF, whereas Kras mutant cells had increased amounts of basal pAkt but responded less to stimulation (Fig. 2B and fig. S10B ). U73122 and PI-90 blocked the GM-CSF-dependent increase in ERK phosphorylation in wild-type and Mx1-Cre, Kras G12D BMMPCs; however, neither inhibitor altered PMA-dependent activation of ERK (Fig. 2C and fig. S11, A and B) . Furthermore, U73122 blocked the GM-CSF-dependent phosphorylation of Akt in wild-type BMMPCs, reduced basal amounts of pAkt in Mx1-Cre, Kras G12D cells, and inhibited the activation of Akt by GM-CSF in these cells (Fig. 2C and figs. S3D and S11B). Together with the results of the phospho-flow cytometry and shRNA experiments presented earlier, these data place PLC-g upstream of PI3K in GM-CSF signaling in wild-type and Mx1-Cre, Kras G12D mutant hematopoietic cells. We next asked whether the PLC-g effector Ca 2+ and calmodulindependent protein kinase II (CaMKII) was required for efficient ERK phosphorylation in Mx1-Cre, Kras G12D BMMPCs by assessing the inhibitory effects of 2-APB (an IP 3 receptor antagonist) and KN-62 (a CaMKII inhibitor) (32) . Like U73122, 2-APB and KN-62 blocked GM-CSF-dependent ERK phosphorylation, whereas BIM I did not (fig. S12, A and B). These data are consistent with a study showing that 2-APB and KN-62 blocked GM-CSFdependent ERK activation in wild-type hematopoietic cells (32) .
To assess the functional requirements for PLC-g and PI3K in myeloid progenitors, we grew CFU-GM colonies in methylcellulose medium containing a saturating concentration of GM-CSF together with JakI, PI-90, U73122, or the Akt inhibitor Akt VIII. These studies revealed dose-dependent inhibition of CFU-GM growth of both wild-type and Mx1-Cre, Kras G12D bone marrow cells in the presence of 0.1 to 10 mM JakI, U73122, or PI-90 (Fig. 2D) . We observed substantial inhibition of CFU-GM growth in cells exposed to 1 to 10 mM of each inhibitor, which correlated with biochemical inhibition of GM-CSFdependent ERK phosphorylation in BMMPCs (Fig. 2D and fig. S8 ). In contrast, Akt VIII had modest effects on CFU-GM growth at concentrations that blocked Akt phosphorylation in cultured BMMPCs (Fig. 2D and fig. S8B ).
Together, these data suggest that phosphorylation of the GM-CSF receptor by JAK2 generates docking sites for PLC-g and PI3K binding. These proteins, in turn, generate DAG, Ca 2+ , and PIP 3 (phosphatidylinositol 3,4,5-trisphosphate), which function upstream of Ras in the activation of the Raf-MEK-ERK pathway in wild-type and Mx1-Cre, Kras G12D cells. Furthermore, multiple lines of evidence place PLC-g upstream of PI3K in modulating the response of myeloid cells to GM-CSF. First, U73122 inhibited Akt phosphorylation, whereas PI-90 only partially reduced PLC-g activation (Figs. 1D and 2C and fig. S7 ). Second, knockdown of PLC-g2 markedly impaired the GM-CSF-dependent phosphorylation of Akt and ERK ( Fig. 2A) . Third, U73122 inhibited CFU-GM progenitor growth, whereas Akt VIII had only modest effects (Fig. 2D) .
RasGRPs potentiate the phosphorylation of ERK
We next sought DAG effectors that might contribute to the activation of Ras-ERK signaling in BMMPCs. PKC isoforms and RasGRPs contain DAGbinding domains and regulate the generation of Ras-GTP; however, the PKC inhibitor BIM I did not inhibit cytokine-induced ERK activation in M
-bone marrow cells (Fig. 1, A to C, and fig. S2A ) or in cultured BMMPCs ( fig. S8) . Furthermore, GM-CSF stimulation did not alter the phosphorylation states of multiple PKC isoforms in BMMPCs ( fig. S13) .
We next asked whether members of the RasGRP family of GEFs might link cytokine receptor activation to the stimulation of Ras and ERK signaling. Quantitative polymerase chain reaction (PCR) analysis showed that BMMPCs express RasGrp3 and RasGrp4, but not RasGrp1. Mx1-Cre, Kras G12D cells expressed substantially increased amounts of Rasgrp3 mRNAs compared to wild-type cells, and Western blotting analysis showed that they had increased amounts of RasGRP3 protein compared to wild-type cells (Fig. 3, A and B,  and fig. S14 ). We used RNAi to reduce RasGRP3 and RasGRP4 abundances in BMMPCs, and assessed the effects on GM-CSF-dependent ERK phosphorylation ( Fig. 3C and fig. S14 ). Knocking down RasGRP4 modestly reduced the extent of ERK phosphorylation in wild-type BMMPCs, whereas knockdown of RasGRP3 had minimal effects (Fig. 3C and fig. S14 ). In contrast, knockdown of either RasGRP3 or RasGRP4 inhibited GM-CSF-dependent ERK phosphorylation in Mx1-Cre, Kras G12D cells (Fig. 3C and fig. S14 ).
PLX4720 partially reverses the inhibitory effects of U73122 and PI-90 in bone marrow cells
The potent Raf inhibitor PLX4032 (also known as vemurafenib) is a highly promising treatment for human cancers with somatic BRAF mutations (33, 34) . PLX4032 and the related compound PLX4720 selectively reduce pERK abundance in cells expressing oncogenic B-Raf proteins, but paradoxically activate signaling in the context of wild-type B-Raf through allosteric effects on homo-and heterodimers of c-Raf and B-Raf (35) (36) (37) . Consistent with studies in other cell types, we found that incubating bone marrow cells from wild-type or Mx1-Cre, Kras G12D mice with PLX4720 increased the abundance of pERK in response to GM-CSF compared to that in untreated cells (Fig. 3D and fig. S15 ). PLX4720 also partially antagonized the inhibitory effects of PI-90 and U73122 on GM-CSF-dependent ERK phosphorylation, but, as expected, did not overcome inhibition by PD0325901 (Fig. 3D and fig. S15 ). Together with data presented earlier, these findings further support a model in which PLC-g and PI3K link the activated GM-CSF receptor to ERK activation through Ras and Raf.
Inhibitors of PLC-g and PI3K perturb SCF signaling in immature hematopoietic cells
The transplantation of purified populations of Mx1-Cre, Kras G12D bone marrow cells into recipient mice showed that HSCs initiate and maintain leukemic growth in vivo (38, 39) . To determine the extent to which PLC-g and PI3K were essential for efficient ERK activation in a population of mice showed robust ERK activation in response to SCF (Fig. 4 , A to C). As expected, PD0325901 abrogated ERK phosphorylation in response to SCF or the combination of SCF and PMA (Fig. 4A) . SCF-induced ERK activation in KLS 48 − cells was also sensitive to inhibition by PI-90 and U73122; however, KLS 48 − cells that were also stimulated with PMA had increased pERK abundance despite the presence of either inhibitor (Fig. 4, B and C) . U73343, a structural analog of U73122 that does not inhibit PLC-g activity, had no effect on SCF-dependent ERK phosphorylation in KLS 48 − cells (fig. S16 ). These results are consistent with the data from experiments with BMMPCs showing that PLC-g and PI3K function upstream of DAG in ERK activation.
In vivo treatment of mice with a PI3K inhibitor reduces GM-CSF-dependent ERK activation in primary bone marrow cells
GDC-0941 is a PI3K inhibitor that is being evaluated as an anticancer agent in humans (40) . To investigate whether in vivo treatment with a clinical PI3K inhibitor might affect Raf-MEK-ERK signaling in bone marrow, we administered GDC-0941 to wild-type mice at an oral dose (100 mg/kg) that was efficacious in preclinical models (n = 3 per time point) and euthanized the mice 2 or 6 hours later. Mice that received PD0325901 (5 mg/kg) served as a positive control in this experiment. Treatment with a single dose of either GDC-0941 or PD0325901 markedly reduced the extent of ERK phosphorylation in cells that were stimulated with GM-CSF ex vivo, but had no effect on STAT5 (signal transducer and activator of transcription 5) phosphorylation (Fig. 5, A and B) . These pharmacodynamic data demonstrate that administering a therapeutically relevant dose of a PI3K inhibitor to mice reduces the ability of bone marrow cells to activate ERK in response to cytokines.
R E S E A R C H A R T I C L E

DISCUSSION
Here, we demonstrated cooperativity between PLC-g and PI3K in linking GM-CSF receptor activation to Ras and ERK signaling in primary hematopoietic cells (Fig. 6 ). This module regulates growth factor responses in immature and differentiated cells, and is engaged by cytokine receptors with and without intrinsic RTK activity, suggesting that it may represent a general mechanism for activating the Raf-MEK-ERK cascade. Inhibitors of PLC-g and PI3K interfered with ERK phosphorylation in an enriched population of normal and Mx1-Cre, Kras G12D bone marrow cells that included leukemia-initiating cells. Despite having markedly increased basal amounts of Ras-GTP, cells expressing oncogenic K-Ras G12D from the endogenous genetic locus remained dependent on PLC-g and PI3K for efficient ERK activation in response to GM-CSF and SCF. Studies of hematopoietic progenitor colony growth, and of cytokine signaling after treatment with a PI3K inhibitor in vivo, confirmed the physiological relevance of our in vitro observations. Together, these data have implications for clinical trials that combine Raf-MEK-ERK and PI3K-Akt-mTOR or PLC-g inhibitors, as well as for nascent efforts to develop small molecules that directly target oncogenic Ras proteins. We addressed additional questions regarding the role of PLC-g in the activation of the Raf-MEK-ERK pathway by GM-CSF. First, our data showing that PMA overcame the inhibitory effects of U73122 support an essential role for DAG in the efficient activation of ERK. We also implicated RasGRPs as potential effectors of DAG. Second, the ability of U73122 to reduce Ras-GTP loading in wild-type bone marrow cells and of PLX4720 to rescue ERK phosphorylation in the presence of this inhibitor identified Ras and Raf as linking PLC-g proteins to the activation of MEK and ERK. Third, we showed that PI3K was also required to activate Ras and ERK in response to cytokines. Finally, we showed that primary hematopoietic cells with endogenous amounts of oncogenic K-Ras G12D remained dependent on PLC-g and PI3K signaling for efficient ERK activation despite having increased basal amounts of Ras-GTP compared to those in wild-type cells.
Ras-GTP binds to and activates class I and II PI3Ks, which, in turn, are crucial for Ras-induced transformation of many cell types. For example, engineering oncogenic Ras proteins with "second site" amino acid substitutions that eliminate or severely impair PI3K binding results in defective transforming activity (41) (42) (43) , and strains of mice lacking the regulatory p85 subunit of PI3K or carrying a "knock-in" mutation in the catalytic p110a subunit that abrogates Ras binding are resistant to tumorigenesis driven by expression of oncogenic K-Ras G12D (44, 45) . These and other data establish PI3Ks as critical effectors of oncogenic Ras proteins in cancer pathogenesis.
However, PI3K inhibitors can also block the activation of Ras and ERK in some contexts (46) (47) (48) (49) (50) . Three independent studies of cultured epithelial cell lines found that PI3K was essential for efficient ERK activation only at low concentrations of growth factor, which likely reflects physiologic conditions in most normal tissues (46, 49, 50) . Duckworth and Cantley (46) also identified a PI3K-independent PLC-g-PKC pathway in 3T3 cells that was engaged at high concentrations of platelet-derived growth factor and overcame the inhibitory effects of wortmannin (a PI3K inhibitor). In contrast, our data demonstrate that PLC-g and PI3K cooperatively activate ERK in primary hematopoietic cells through a mechanism that is very likely independent of PKCs. These observations suggest that the architecture of signaling networks downstream of activated growth factor receptors varies in a tissue-specific manner. Our data showing that U73122 and PLC-g2 knockdown greatly reduced GM-CSF-dependent Akt phospho- rylation in BMMPCs place PLC-g upstream of PI3K; however, PI-90 also modestly reduced the extent of PLC-g phosphorylation, which raises the possibility that PI3K functions in a "feed-forward" manner to amplify the signal from PLC-g (Fig. 6) . We speculate that lipid second messengers generated by PI3K and PLC-g after recruitment to growth factor receptors, specifically PIP 3 and DAG, cooperate to localize and assemble signaling complexes that efficiently activate exchange factors, Ras, and the Raf-MEK-ERK pathway. In agreement with the GM-CSF network that we described here for myeloid cells, we previously showed that the increased abundance of RasGRP1 links cytokine receptors to Ras in T cell leukemia (51) . These data suggest that different RasGRP family members regulate Ras activation in response to cytokines in distinct hematopoietic lineages.
It is unclear why constitutively increased amounts of Ras-GTP in Mx1-Cre, Kras G12D hematopoietic cells only minimally activate Raf-MEK-ERK signaling. One provocative idea is that flux through the pathway is increased, but cells use negative feedback mechanisms that reduce basal amounts of pERK. Alternatively, we speculate that efficient activation of Raf-MEK-ERK signaling requires that Ras both bind to GTP and be localized at signaling complexes on activated cytokine receptors. Lipid second messengers, in particular PIP 3 , can recruit and retain K-Ras and other polybasic proteins to specific domains within the plasma membrane (52) . PIP 3 might also colocalize PH domain-containing proteins, including SOS, RasGRPs, and other guanine nucleotide exchange factors, within membrane nanoclusters to promote the assembly of signaling complexes on activated receptors (53, 54) . It is likely that wild-type Ras localizes to activated cytokine receptors at which GEFs mediate GTP loading. In contrast, whereas oncogenic Ras accumulates in its GTP-bound conformation in the absence of growth factors, our data are consistent with the idea that it still requires a localization signal that is dependent on PLC-g and PI3K to efficiently activate the Raf-MEK-ERK pathway.
RasGRP4, a Ras-specific GEF that is highly abundant in myeloid cells, is mutated in some cases of acute myeloid leukemia and modulates Ras-GTP amounts in response to PMA (55) . Our data support a role for RasGRP4 in activating Ras and ERK in the physiologic setting of GM-CSF signaling. Whereas RasGRP4 played a dominant role in wild-type cells, we found that Mx1-Cre, Kras G12D BMMPCs had increased amounts of RasGRP3 and become dependent on this isoform, which suggests that K-Ras G12D remodels signaling networks in unanticipated ways. The observation that PLC-g engaged Ras though RasGRPs in myeloid cells is consistent with previous studies in Tand B lymphocytes in which the PLC-g-dependent product DAG plays a critical role in recruiting RasGRP1 and RasGRP3 to the plasma membrane (56) .
These unexpected results also raise the intriguing possibility that inhibiting the biochemical output of proteins upstream of oncogenic Ras may represent a viable approach for treating some cancers, particularly those that are highly responsive to growth factors. Maurer et al.
(5) used fragment-based lead discovery to develop chemical inhibitors to a previously uncharacterized binding pocket on the surface of Ras. DCA1, a compound from this screen, inhibits Ras activation by interfering with SOS-mediated guanine nucleotide exchange and also likely has activity against other GEFs (5). The results of our study support testing the ability of DCA1 and related compounds to block GM-CSF-and SCF-mediated ERK activation in wild-type and Mx1-Cre, Kras G12D cells to further evaluate the potential of this general therapeutic strategy.
Preclinical data supporting the simultaneous targeting of the Raf-MEK-ERK and PI3K-Akt-mTOR signaling pathways in KRAS mutant cancers (44) are currently being translated clinically. Although this approach may enhance tumor killing, our data suggest that suppression of cytokine signaling in normal hematopoietic stem and progenitor cells will emerge as a clinically relevant adverse effect of PI3K inhibition. This potential toxicity may become especially problematic when PI3K inhibitors are used in JAK2 γ Fig. 6 . Proposed mechanism of cytokine-induced Ras and ERK activation in hematopoietic cells expressing WT and oncogenic K-Ras. In response to the binding of GM-CSF to its receptor, JAK2 transphosphorylates multiple tyrosine residues on the b common chain of the GM-CSF receptor, creating docking sites for adaptor proteins and signaling molecules. PLC-g1 and PLC-g2 are recruited to the receptor complex and become activated, generating DAG. The p85 regulatory subunit of PI3K binds to the receptor through adaptor proteins, which results in PI3K activation and PIP 3 production. Second messengers generated by PI3K and PLC-g stimulate nucleotide exchange on Ras, likely by both localizing Ras to the plasma membrane and activating RasGRPs. The DAG mimetic PMA activates Ras and ERK independently of PLC-g and PI3K. This scheme does not directly address the interaction between PLC-g and PI3K; however, multiple lines of evidence suggested that PLC-g is upstream of PI3K. The levels at which the different inhibitors used in this study exerted their effects are indicated by dashed red bars. Raf activation by PLX4720 is indicated as a dashed green arrow. Studies using many of these inhibitors support a similar role for PLC-g and PI3K in linking the activated RTK c-Kit to Ras and ERK signaling.
combination with other anticancer drugs that suppress blood cell production. If this proves true, Akt or mTOR inhibitors may have a better therapeutic index in certain clinical settings.
Finally, because some primary cells that have amounts of oncogenic Ras similar to that of wild-type Ras remain dependent on extracellular stimuli to activate downstream effector pathways, inhibitors of proteins upstream of Ras may be effective in some cancers. For example, PLC-g and PI3K are attractive therapeutic targets in JMML, CMML, and other MPNs that have a high incidence of RAS mutations in which hematopoietic growth factors play a central role in driving aberrant growth (9) . This general paradigm may also apply to nonhematologic cancers that remain dependent on growth factors and other extracellular stimuli that contribute to activate oncogenic signaling pathways.
MATERIALS AND METHODS
Antibodies
Antibodies specific for pERK (9101), RasGRP3 (3334), pPKCa (pT638/641; 9375), pPKCb (pS660; 9371), pPKCd (pT505; 9374), pPKCq (pT538; 9377), and b-actin (4967) were purchased from Cell Signaling Technology; antibody against pAkt (pS473; 44-621G) was from Invitrogen; antibody against Ras (clone Ras10) (05-516) was from Millipore; antibody specific for RasGRP4 (pab0554-1) was from Covalab; antibody against PLC-g1 (sc-7290) was from Santa Cruz Biotechnology; and antibody against PLC-g2 (bs-3532R) was from Bioss. Horseradish peroxidase (HRP)-conjugated polyclonal goat anti-rabbit immunoglobulin G (IgG; P0448) was from DakoCytomation, and HRP-conjugated sheep anti-mouse IgG (NA931V) was from GE Healthcare. In flow cytometry experiments, primary antibodies were detected with fluorescein isothiocyanate (FITC)-conjugated anti-rabbit IgG (711-096-152) or allophycocyanin (APC)-conjugated anti-rabbit IgG (711-136-152), both of which were purchased from Jackson ImmunoResearch. Phosphorylated STAT5 (pY694) was detected with an antibody directly conjugated to Alexa Fluor 647 (BD Biosciences, #612599), and antibodies specific for pPLC-g1 (bs-3343R) and pPLC-g2 (bs-3339R) were purchased from Bioss. Cell surface proteins were detected with directly conjugated antibodies from BD Pharmingen [for CD11b/Mac1 (553311) and Gr1 (553128)] and eBioscience [for CD117/c-Kit (15-1171-320)]. Antibody against CD16 and CD32 (BD Biosciences, 553142) was used to block Fc receptors.
Chemical inhibitors and ligands
The PI3K inhibitors PI-90, PI-103, AS605240 (for PI3Ka and PI3Kg), TGX 115 (PI3Kb), IC87114 (PI3Kd), and SW13 (PI3Kd) (all used at a final concentration of 5 mM) were synthesized in the Shokat laboratory. JakI (catalog #420099), SU6656 (#572635), PP2 (#529576), BIM I (#203291), bryostatin (#203811), U73122 (#662035), and U73343 (#662041) were purchased from Calbiochem; PMA (catalog #P8139), 2-APB (#D9754), and KN-62 (#I2142) were obtained from Sigma-Aldrich; PD0325901 was provided by Pfizer Inc.; GDC-0941 was provided by Genentech Inc.; and PLX4720 was obtained from Plexxikon Inc.
siRNA oligonucleotides and reagents
Specific siRNAs for RasGRP3 (MSS216067), RasGRP4 (MSS239172), the Negative Universal Control low GC (12935-110), and Lipofectamine RNAiMAX (13778-150) were purchased from Invitrogen.
shRNA oligonucleotides and reagents
The shRNAs specific for PLC-g1 and PLC-g2 were generated according to published rules (57) . The sequences of the PLC-g hairpins used to generate the data shown in Fig. 2A and fig. S6 are provided in table S1.
Mice
Kras
LSL-G12D mice were described previously (58) . Mx1-Cre, Kras LSL-G12D mice (10) received a single 250-mg injection of polyinosinic-polycytidilic acid [poly(I:C), Sigma] at 21 days of age to induce Kras G12D expression. All animals were maintained in the rodent barrier facility at the University of California, San Francisco (UCSF), and the UCSF Committee on Animal Research approved the experimental procedures.
Harvesting and stimulation of bone marrow cells
Bone marrow cells were harvested from mouse femurs into Iscove's modified Dulbecco's medium (IMDM) containing 1% bovine serum albumin (BSA; Sigma-Aldrich). Erythrocytes were lysed and mononuclear cells were incubated at 37°C for 2 to 2.5 hours. Where indicated, the cells were stimulated with the following murine cytokines (all purchased from PeproTech) at the indicated concentrations: GM-CSF (10 or 1 ng/ml), SCF (100 ng/ml), and M-CSF (10 ng/ml). PMA and bryostatin were used at concentrations of 200 ng/ml and 500 nM, respectively. For in vitro experiments, bone marrow cells were harvested as described earlier, starved of cytokines and serum for 90 min, and incubated for 30 min with each inhibitor before being stimulated with GM-CSF (10 ng/ml) or SCF (100 ng/ml) for 10 min (for primary bone marrow cells) or 15 min (for cultured BMMPCs).
Flow cytometric analysis and myeloid progenitor cell proliferation
For flow cytometry, cells were fixed, permeabilized, and analyzed as described previously, with staining of Sca1 and CD48 after formaldehyde fixation and before methanol permeabilization (15, 21) {REF: Lyubynska}. CFU-GM colonies were grown from bone marrow cells in methylcellulose medium M3231 (STEMCELL Technologies) and scored at day 8 by indirect microscopy.
Culture and stimulation of BMMPCs
BMMPCs were grown in macrophage medium as described previously (29, 59) . After reaching confluence, the cells were passaged once and grown for an additional 2 to 3 days. Before being stimulated, BMMPC culture medium was replaced with minimal medium (IMDM supplemented with 1% BSA) for 4 hours. Next, supernatants were removed, 3 ml of phosphate-buffered saline (PBS)-based dissociation buffer (Gibco) was added, and the plates were placed at 37°C for 5 min. Cells were then gently scrapped off the plates with a rubber scrapper, washed once with PBS, and resuspended in IMDM, 1% BSA for stimulation.
Western blotting analysis and Ras-GTP assays
After stimulation, cells were pelleted and lysed in 1% NP-40 buffer containing 30 mM NaF, 30 mM b-glycerophosphate, 20 mM Na 4 P 2 O 7 , 1 mM Na 3 VO 4 , aprotinin (10 mg/ml), leupeptin (10 mg/ml), and 1 mM phenylmethylsulfonyl fluoride. Protein concentrations were determined with the BCA Protein Assay Kit (Pierce). Samples were resolved on precast Criterion polyacrylamide gels (Bio-Rad) and transferred to Immobilon-P membranes (Millipore). After incubation with the appropriate antibodies and washing, the blots were treated with ECL (Amersham Biosciences) or ECL Plus (GE Healthcare) to visualize target proteins. Ras-GTP abundance was measured with a Raf-Ras binding domain (RBD) pull-down assay, as described previously (59, 60) .
Analysis of the effects of PLX4720 on ERK activation
BMMPCs were starved of serum and cytokines overnight, resuspended in IMDM, 1% BSA medium, incubated with 5 mM PI-90 or 5 mM U73122 for 30 min, and then stimulated with GM-CSF in the absence or presence of 5 mM PLX4720 for 15 min. Cells were then lysed and subjected to Western blotting analysis to determine ERK activation.
Analysis of RasGRP expression by quantitative PCR
Total RNA was extracted with an RNeasy kit (Qiagen) according to the manufacturer's instructions. After quantifying the RNA with a NanoDrop spectrophotometer, we performed RT-PCR assays with standard procedures and random primers (Invitrogen). Real-time (TaqMan) RT-PCR analysis was performed with an ABI TaqMan 7300 (Applied Biosystems) with specific TAMRA (tetramethylrhodamine)-labeled probes. All steps were performed in AmpliTaq Gold Mix (Applied Biosystems). During the exponential phase of the PCR, the crossing threshold (C t ) was determined for each amplification curve. DNAs from cells not stimulated were used as calibrators. All results were normalized to those of the gene encoding b-actin and were expressed as ratios related to the expression of the gene of interest in the calibrator. The relative quantification ratio was evaluated with quantification based on the DDC t method (51). RasGRP1-specific primers and probe (Operon) were designed as follows: forward, aagctccaccaactacagaact; reverse, agggagatgaggtccttgagat; probe, ccacatgaaatcaataaggttctcggtgag[TAMRA-6-FAM]. Expression of the genes encoding b-actin and RasGRP3, and RasGRP4, was determined with the following primer-probe sets purchased from Applied Biosystems: Mm01205647_g1 (b-actin), Mm01233143_m1 (RasGRP3), and Mm00460898_m1 (RasGRP4).
RasGRP knockdown by RNAi
For RNAi experiments, BMMPCs (1 × 10 6 ) were replated in 60 × 15-mm petri dishes (BD Biosciences, #351007) in 4 ml of macrophage culture medium containing M-CSF 1 day before the experiment. After 24 hours, the medium was aspirated and replaced with 2.5 ml of IMDM, 1% BSA. After 3 hours, a mixture containing 5 to 20 pmol (0.75 to 3 ml) of each siRNA duplex together with 12 ml of Lipofectamine RNAiMAX solution suspended in 500 ml of IMDM, 1% BSA was added to each plate. Cells were mixed gently and incubated for 3 hours at 37°C in 5% CO 2 before serum was added to a final concentration of 10%. After 36 hours, cells were harvested with cell dissociation buffer as described earlier, resuspended in 1 ml of IMDM, 1% BSA medium, and transferred to microfuge tubes for stimulation with GM-CSF for 15 min. Cells were then spun down at 1130g, lysed, and subjected to SDS-polyacrylamide gel electrophoresis, transfer, and Western blotting analysis as described earlier.
Retrovirus production and knockdown of PLC-g1 and PLC-g2 by shRNA Human embryonic kidney (HEK) 293T cells were transfected with the calcium phosphate transfection protocol as described previously (7) to produce retrovirus containing LMN vectors (61) expressing both GFP and shRNA constructs specific for PLC-g1 or both mCherry and shRNA constructs specific for PLC-g2. Cells were cultured for 72 hours to produce a high viral titer, and the supernatant was collected. Bone marrow cells from wild-type mice were then freshly harvested in IMDM, 10% fetal bovine serum (FBS) and spin-infected with the virus supernatant at 1000g for 2 hours at room temperature on six-well plates containing 4 × 10 6 cells per construct. After spin infection, cells were incubated for 5 hours at 37°C and were then transferred to 15-ml tubes. After centrifugation at 1300 rpm for 5 min, the supernatant was removed and replaced with fresh macrophage culture medium [IMDM, 20% bovine growth serum, containing M-CSF (30 ng/ml)], and the cells were plated again in six-well plates and cultured for 24 hours. The next day, more viruses were collected, and the spin infection protocol was repeated. After changing the culture medium, cells were grown for 5 days until macrophages were generated. G418 (0.5 mg/ml) was added to the cells for 5 days to select the transduced cells. G418-containing medium was replaced by macrophage medium containing M-CSF (30 ng/ml), and cells were cultured for an additional 7 to 8 days until the macrophages reached 80% confluency. Cells were then cultured in starving medium (IMDM, 1% BSA) overnight and then were collected before being stimulated with GM-CSF (10 ng/ml) for 15 min and then pelleted for Western blotting analysis, as described earlier.
SUPPLEMENTARY MATERIALS
www.sciencesignaling.org/cgi/content/full/6/304/ra105/DC1 Fig. S1 . Table S1 . Sequences of PLC-g1-and PLC-g2-specific shRNAs.
